EMCURE

Emcure Pharmaceuticals Share Price

₹1,279.05 -26.7 (-2.04%)

21 Nov, 2024 14:03

SIP TrendupStart SIP in EMCURE

Start SIP

Performance

  • Low
  • ₹1,278
  • High
  • ₹1,324
  • 52 Week Low
  • ₹1,225
  • 52 Week High
  • ₹1,580
  • Open Price₹1,320
  • Previous Close₹1,306
  • Volume73,977

Investment Returns

  • Over 1 Month -14.3%
  • Over 3 Month -3.91%
  • Over 6 Month + 26.98%
  • Over 1 Year + 26.98%
SIP Lightning

Smart Investing Starts Here Start SIP with Emcure Pharmaceuticals for Steady Growth!

Invest Now

Emcure Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 42.6
  • PEG Ratio
  • -
  • Market Cap Cr
  • 24,187
  • P/B Ratio
  • 7.7
  • Average True Range
  • 57.46
  • EPS
  • 30.36
  • Dividend Yield
  • 0
  • MACD Signal
  • -12.41
  • RSI
  • 35.01
  • MFI
  • 35.07

Emcure Pharmaceuticals Financials

Emcure Pharmaceuticals Technicals

EMA & SMA

Current Price
₹1,279.05
-26.7 (-2.04%)
pointer
  • stock-down_img
  • Bullish Moving Average 0
  • stock-up_img
  • Bearish Moving Average 11
  • 20 Day
  • ₹1,394.66
  • 50 Day
  • ₹1,403.41
  • 100 Day
  • -
  • 200 Day
  • -

Resistance and Support

1311.3 Pivot Speed
  • R3 1,374.75
  • R2 1,355.45
  • R1 1,330.60
  • S1 1,286.45
  • S2 1,267.15
  • S3 1,242.30

What's your outlook on Emcure Pharmaceuticals?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Emcure Pharmaceuticals manufactures and markets a wide range of pharmaceutical products, including generics, biosimilars, and injectables. With a global presence in 70+ countries, it focuses on affordable healthcare solutions across therapeutic areas like cardiology, oncology, and women’s health.

Emcure Pharmaceuticals Ltd has an operating revenue of Rs. 7,256.12 Cr. on a trailing 12-month basis. An annual revenue growth of 2% is not great, Pre-tax margin of 12% is healthy, ROE of 21% is exceptional. The company has a reasonable debt to equity of 30%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 46 which is a POOR score indicating inconsistency in earnings, a RS Rating of 35 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 52 indicates it belongs to a fair industry group of Medical-Supplies and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Emcure Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-07 Quarterly Results
2024-08-13 Quarterly Results

Emcure Pharmaceuticals F&O

Emcure Pharmaceuticals Shareholding Pattern

78.08%
3.3%
0.49%
2.91%
5.01%
10.21%

About Emcure Pharmaceuticals

  • NSE Symbol
  • EMCURE
  • BSE Symbol
  • 544210
  • Managing Director & CEO
  • Mr. Satish Ramanlal Mehta
  • ISIN
  • INE168P01015

Similar Stocks to Emcure Pharmaceuticals

Emcure Pharmaceuticals FAQs

Emcure Pharmaceuticals share price is ₹1,279 As on 21 November, 2024 | 13:49

The Market Cap of Emcure Pharmaceuticals is ₹24186.6 Cr As on 21 November, 2024 | 13:49

The P/E ratio of Emcure Pharmaceuticals is 42.6 As on 21 November, 2024 | 13:49

The PB ratio of Emcure Pharmaceuticals is 7.7 As on 21 November, 2024 | 13:49

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23